Home/Companies/Biotech/GreyWolf Therapeutics

GreyWolf Therapeutics

Biotech·

United Kingdom·Active·8yr hold

Entry

2018

Hold

8yr

Status

Active

Who owns GreyWolf Therapeutics?

GreyWolf Therapeutics is a British Biotech company, currently owned by Earlybird Venture Capital since 2023 and Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY

Most recent investor

Andera Partners

BioDiscovery 5 · 2017 · VC

2 ownership periods · full history below

Key facts

HQUnited Kingdom

SectorBiotech

Websitewww.greywolftherapeutics.com

Ownership history

2 ownership periods · co-invest detected

Active

Co-held by Andera Partners and Earlybird Venture Capital since 2018.

Co-invest · 2 holders · 2018 · present

Andera PartnersActive

2018 · present(8yr) · BioDiscovery 5 · 2017 · VC

Earlybird Venture CapitalActive

2023 · present(3yr) · Earlybird Health · 2017 · VC

More from BioDiscovery 5

Other portfolio companies in the same fund.

to Public market (NYSE IPO ticker EVMN)

to Public market (Nasdaq IPO ticker AGMB)

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare

Active

The Carlyle GroupChina

Adagene

Active

General AtlanticChina

Advanced Cell Diagnostics

Questions

Who owns GreyWolf Therapeutics?

GreyWolf Therapeutics is currently owned by Earlybird Venture Capital and Andera Partners, through BioDiscovery 5, since 2023.

When did Earlybird Venture Capital and 1 other acquire GreyWolf Therapeutics?

Earlybird Venture Capital and 1 other acquired GreyWolf Therapeutics in 2023.

Who has owned GreyWolf Therapeutics over time?

GreyWolf Therapeutics has been through 2 private-equity ownership periods: Andera Partners · via BioDiscovery 5 · since 2018; Earlybird Venture Capital · via Earlybird Health · since 2023.

Look up another firm or company

Data refreshed weekly · Sourced from public filings · Report an issue